

## EQA round: KD3/23 - Glycated Haemoglobin

Deadline: 28.7.2023

Setup: groups - manufacturer of kit; minimal size of the groups n = 5

RoM = robust average

SD = standard deviation

CV = coefficient of variation

N<sub>tot</sub> = total number of the resultsN<sub>out</sub> = number of the results removed before calculation

AV = assigned value

CVP = consensus of all participants

U<sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)D<sub>max</sub> = acceptable difference

LL = lower limit

UL = upper limit

N<sub>eva</sub> = number of the results assessedN<sub>suc</sub> = number of successful resultsS<sub>rel</sub> = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	Comparability						N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub> [%]
							AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL				
<b>(220) Haemoglobin A<sub>1c</sub></b>	[mmol/mol]				141								137	134	98
<b>Sample A</b>		32,8	1,6	4,8	141								137	135	99
(14) Bio-Rad		33	1,7	5	41	0	CVP	32,8	0,32	12%	28,8	36,8	41		
(25) TOSOH		33,5	1	3	44	0	CVP	32,8	0,32	12%	28,8	36,8	44		
(60) Roche		32,1	2,9	9,2	8	0	CVP	32,8	0,32	12%	28,8	36,8	8		
(150) Arkray		31,8	1,2	3,9	37	0	CVP	32,8	0,32	12%	28,8	36,8	37		
Other					11	0							7		
								3x 1, 1x 12, 3x 34, 1x 46, 1x 58, 1x 149, 1x 162							
<b>Sample B</b>		74,5	2,9	3,9	141								137	136	99
(14) Bio-Rad		76,1	1,9	2,5	41	0	CVP	74,6	0,58	12%	65,6	83,6	41		
(25) TOSOH		74,9	1,5	2	44	0	CVP	74,6	0,58	12%	65,6	83,6	44		
(60) Roche		76,9	2	2,6	8	0	CVP	74,6	0,58	12%	65,6	83,6	8		
(150) Arkray		71,4	2,5	3,5	37	0	CVP	74,6	0,58	12%	65,6	83,6	37		
Other					11	0							7		
								3x 1, 1x 12, 3x 34, 1x 46, 1x 58, 1x 149, 1x 162							